Search Immortality Topics:

Page 30«..1020..29303132..4050..»

Leonard Weinberger MD Doctor Profile & Reviews …

Posted: March 9, 2019 at 4:44 am

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UHs policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Leonard Weinberger did not disclose any Outside Relationships with Industry.

Read the original post:
Leonard Weinberger MD Doctor Profile & Reviews ...

Recommendation and review posted by G. Smith

SOD1 gene – Genetics Home Reference – NIH

Posted: March 9, 2019 at 4:42 am

At least 200 mutations in the SOD1 gene have been found to cause amyotrophic lateral sclerosis (ALS), a condition characterized by progressive muscle weakness, a loss of muscle mass, and an inability to control movement. Most of these mutations change one of the protein building blocks (amino acids) in the superoxide dismutase enzyme. About half of all Americans with ALS caused by SOD1 gene mutations have a particular mutation that replaces the amino acid alanine with the amino acid valine at position 5 in the enzyme, written as Ala5Val or A5V. (Because of variations in the ways amino acids are counted in proteins, this mutation is sometimes called Ala4Val or A4V.) ALS caused by the A5V mutation is generally associated with a shorter life expectancy compared with ALS caused by other genetic mutations.

ALS is caused by the death of nerve cells that control muscle movement (motor neurons). It is unclear why these cells are particularly sensitive to SOD1 gene mutations. Researchers have suggested several ways in which the altered enzyme may cause the death of motor neurons. These possibilities include an increase in harmful superoxide radicals, increased production of other types of toxic radicals, increased cell death, or accumulation of clumps (aggregates) of misfolded superoxide dismutase that may be toxic to cells.

Read more from the original source:
SOD1 gene - Genetics Home Reference - NIH

Recommendation and review posted by G. Smith

METIS Precision Medicine The one gene company

Posted: March 9, 2019 at 4:42 am

METISis a B-corp* founded in April 2017 by the confluence of a handful of scientists, among the leaders of oncogene research, and a group of visionary investors with the mission of translating cancer research findings into precision medicine in cancer treatments.

Backed by over three decades of research focused on a specific oncogene, METIS benefits from a profound knowledge of the biology and pathology driven by the oncogene MET, including cancer.

METIS is developing human anti-MET antibodies with the potential to be first-in class to treat diseases with a significant unmet medical need.

The most advanced anti-MET antibody - hOA-DN30 - has proven to be unique and extremely effective against cancer in pre-clinical setting.

METIS owns the intellectual property of a suite of anti-MET monoclonal antibodies (the Platform), targeting the MET oncogene.

(*) Benefit Corporations or B Corps are companies that voluntarily meet the highest standards of purpose, responsibility, and transparency. They go beyond the goal of profit, and innovate to maximize the positive impact on communities, environment, and mankind.

View post:
METIS Precision Medicine The one gene company

Recommendation and review posted by G. Smith

On Human Gene Editing: International Summit Statement

Posted: March 9, 2019 at 4:42 am

Date: Dec. 3, 2015

FOR IMMEDIATE RELEASE

Fundamental research into the ways by which bacteria defend themselves against viruses has recently led to the development of powerful new techniques that make it possible to perform gene editing that is, precisely altering genetic sequences in living cells, including those of humans, at much higher accuracy and efficiency than ever before possible. These techniques are already in broad use in biomedical research. They may also enable wide-ranging clinical applications in medicine. At the same time, the prospect of human genome editing raises many important scientific, ethical, and societal questions.

After three days of thoughtful discussion of these issues, the members of the Organizing Committee for the International Summit on Human Gene Editing have reached the following conclusions:

1. Basic and Preclinical Research. Intensive basic and preclinical research is clearly needed and should proceed, subject to appropriate legal and ethical rules and oversight, on (i) technologies for editing genetic sequences in human cells, (ii) the potential benefits and risks of proposed clinical uses, and (iii) understanding the biology of human embryos and germline cells. If, in the process of research, early human embryos or germline cells undergo gene editing, the modified cells should not be used to establish a pregnancy.

2. Clinical Use: Somatic. Many promising and valuable clinical applications of gene editing are directed at altering genetic sequences only in somatic cells that is, cells whose genomes are not transmitted to the next generation. Examples that have been proposed include editing genes for sickle-cell anemia in blood cells or for improving the ability of immune cells to target cancer. There is a need to understand the risks, such as inaccurate editing, and the potential benefits of each proposed genetic modification. Because proposed clinical uses are intended to affect only the individual who receives them, they can be appropriately and rigorously evaluated within existing and evolving regulatory frameworks for gene therapy, and regulators can weigh risks and potential benefits in approving clinical trials and therapies.

3. Clinical Use: Germline. Gene editing might also be used, in principle, to make genetic alterations in gametes or embryos, which will be carried by all of the cells of a resulting child and will be passed on to subsequent generations as part of the human gene pool. Examples that have been proposed range from avoidance of severe inherited diseases to enhancement of human capabilities. Such modifications of human genomes might include the introduction of naturally occurring variants or totally novel genetic changes thought to be beneficial.

Germline editing poses many important issues, including: (i) the risks of inaccurate editing (such as off-target mutations) and incomplete editing of the cells of early-stage embryos (mosaicism); (ii) the difficulty of predicting harmful effects that genetic changes may have under the wide range of circumstances experienced by the human population, including interactions with other genetic variants and with the environment; (iii) the obligation to consider implications for both the individual and the future generations who will carry the genetic alterations; (iv) the fact that, once introduced into the human population, genetic alterations would be difficult to remove and would not remain within any single community or country; (v) the possibility that permanent genetic enhancements to subsets of the population could exacerbate social inequities or be used coercively; and (vi) the moral and ethical considerations in purposefully altering human evolution using this technology.

It would be irresponsible to proceed with any clinical use of germline editing unless and until (i) the relevant safety and efficacy issues have been resolved, based on appropriate understanding and balancing of risks, potential benefits, and alternatives, and (ii) there is broad societal consensus about the appropriateness of the proposed application. Moreover, any clinical use should proceed only under appropriate regulatory oversight. At present, these criteria have not been met for any proposed clinical use: the safety issues have not yet been adequately explored; the cases of most compelling benefit are limited; and many nations have legislative or regulatory bans on germline modification. However, as scientific knowledge advances and societal views evolve, the clinical use of germline editing should be revisited on a regular basis.

4. Need for an Ongoing Forum. While each nation ultimately has the authority to regulate activities under its jurisdiction, the human genome is shared among all nations. The international community should strive to establish norms concerning acceptable uses of human germline editing and to harmonize regulations, in order to discourage unacceptable activities while advancing human health and welfare.

We therefore call upon the national academies that co-hosted the summit the U.S. National Academy of Sciences and U.S. National Academy of Medicine; the Royal Society; and the Chinese Academy of Sciences to take the lead in creating an ongoing international forum to discuss potential clinical uses of gene editing; help inform decisions by national policymakers and others; formulate recommendations and guidelines; and promote coordination among nations.

The forum should be inclusive among nations and engage a wide range of perspectives and expertise including from biomedical scientists, social scientists, ethicists, health care providers, patients and their families, people with disabilities, policymakers, regulators, research funders, faith leaders, public interest advocates, industry representatives, and members of the general public.* Clinical use includes both clinical research and therapy.

Organizing Committee for the International Summit on Human Gene Editing

David Baltimore(chair)President Emeritus and Robert Andrews Millikan Professor of BiologyCalifornia Institute of TechnologyPasadena

Franoise Baylis Professor and Canada Research Chair in Bioethics and Philosophy Dalhousie UniversityNova Scotia

Paul BergRobert W. and Vivian K. Cahill Professor Emeritus, and Director Emeritus, Beckman Center for Molecular and Genetic MedicineStanford University School of MedicineStanford, Calif.

George Q. DaleySamuel E. Lux IV Chair in Hematology/Oncology, andDirector, Stem Cell Transplantation ProgramBoston Children's Hospital and Dana-Farber Cancer InstituteBoston

Jennifer A. DoudnaInvestigator, Howard Hughes Medical Institute; andLi Ka Shing Chancellor's Chair in Biomedical and Health Sciences, Professor of Molecular and Cell Biology, and Professor of ChemistryUniversity of CaliforniaBerkeley

Eric S. LanderFounding DirectorBroad Institute of Harvard and MITCambridge, Mass.

Robin Lovell-BadgeGroup Leader and HeadDivision of Stem Cell Biology and Developmental GeneticsThe Francis Crick InstituteLondon

Pilar OssorioProfessor of Law and BioethicsUniversity of Wisconsin; andEthics Scholar-in-ResidenceMorgridge Institute for Research Madison

Duanqing PeiProfessor of Stem Cell Biology, and Director General, Guangzhou Institutes of Biomedicine and HealthChinese Academy of SciencesGuangzhou

Adrian ThrasherProfessor of Paediatric Immunology and Wellcome Trust Principal FellowUniversity College London Institute of Child HealthLondon

Ernst-Ludwig WinnackerDirector Emeritus, Laboratory of Molecular Biology, Gene Center, andProfessor Emeritus Ludwig-Maximilians University of MunichMunich

Qi ZhouDeputy Director, Institute of ZoologyChinese Academy of SciencesBeijing

Originally posted here:
On Human Gene Editing: International Summit Statement

Recommendation and review posted by G. Smith

Integrative Medicine & Wellness Center – Atlantic Health

Posted: March 7, 2019 at 1:45 am

Integrative medicine is beneficial for people who want to maintain good health, as well as those who are looking to improve their current health. Evidence-based studies have shown that integrative medicine therapies reduce pain and anxiety, enhance healing, speed recovery, and promote feelings of peace and relaxation.

TheChambers Center for Well Beingoffers more than 20 different healing treatments, including holistic health assessments, nutritional assessments and counseling, lifestyle coaching, acupuncture and massage. Our experts can help you address current health concerns or work with you to prevent health issues such as high blood pressure and cholesterol, weight issues, stress and more.

Our outpatient services are available at two New Jersey locations, including Summit and Morristown, and one physician practice in Morristown.

Atlantic Health System Integrative Medicine offersfree bedside servicesthroughout our hospitals, including therapeutic massage for new moms, acupressure, reflexology, aromatherapy, relaxation techniques and guided imagery. These services are for maternity, cardiac, orthopedic, pediatric, ICU, emergency room and all other patients throughout our hospitals.

See the original post here:
Integrative Medicine & Wellness Center - Atlantic Health

Recommendation and review posted by G. Smith

Integrative Medicine | St. Marys | Lewiston, Maine

Posted: March 7, 2019 at 1:45 am

Integrative Medicine is a specialty that uses all aspects of healing from conventional andcomplementary care. It takes into account the importance of all factors of life on health, both internal (mind, body, and spirit) and external (social and environmental). Integrative Medicine puts a focus on natural, less invasive, and evidence-based care plans for optimal health.

Why consult with an integrative medicine provider?

A 90-minute consultation includes:

Program Director - Anne Brown, MD

Anne Brown, MD has been an internist at St. MarysRegional Medical Center since 1996. She attended medical school at University ofVermont and completed her residency at theOcshner Foundation in New Orleans, Louisiana, and her mind-body training at the Benson-Henry Institute, an affiliate of Massachusetts General Hospital andHarvard Medical School. She completed her fellowship training in 2014 at the University of Arizona to becomea specialist in Integrative Medicine, for which she is is board certified.

Integrative programs we offer:

For more information on Integrative Medicine at St. Mary's, please contact:Dr. Anne BrownSt. Mary's Integrative Medicine & Weight Management198 Main Street, Lewiston, ME 04240(207) 753-4970

Here is the original post:
Integrative Medicine | St. Marys | Lewiston, Maine

Recommendation and review posted by G. Smith


Page 30«..1020..29303132..4050..»